Tags

Type your tag names separated by a space and hit enter

Vasopressin receptor antagonists: potential indications and clinical results.
Curr Opin Pharmacol. 2007 Apr; 7(2):124-9.CO

Abstract

Hyponatremia is a common electrolyte disorder with the potential to cause serious neurological complications. Conventional therapies for hyponatremia have been found to be inconsistently effective. Arginine vasopressin (AVP) is etiologically critical for hyponatremia, and it has been proven that AVP receptor (AVP-R) antagonists normalize serum sodium levels in hyponatremic patients. Additionally, one of these drugs showed potential for reducing mortality in patients with decompensated heart failure and for suppressing the progression of genetic renal disease in animals. The first non-peptide AVP-R antagonist has recently been approved in the United States. It is expected that this approval will accelerate the development of future clinical applications of AVP-R antagonists and open the door to a new era in the treatment of these intractable diseases.

Links

Publisher Full Text
Aggregator Full Text
Aggregator Full Text

Authors+Show Affiliations

Arai Y
Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, 21 Miyukigaoka, Tsukuba-Shi, Ibaraki, Japan.
Fujimori A
No affiliation info available
Sudoh K
No affiliation info available
Sasamata M
No affiliation info available

MeSH

AnimalsAntidiuretic Hormone Receptor AntagonistsArginine VasopressinDrug DesignDrugs, InvestigationalHeart FailureHumansHyponatremiaPolycystic Kidney DiseasesSodium

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17292670

Citation

Arai, Yukinori, et al. "Vasopressin Receptor Antagonists: Potential Indications and Clinical Results." Current Opinion in Pharmacology, vol. 7, no. 2, 2007, pp. 124-9.
Arai Y, Fujimori A, Sudoh K, et al. Vasopressin receptor antagonists: potential indications and clinical results. Curr Opin Pharmacol. 2007;7(2):124-9.
Arai, Y., Fujimori, A., Sudoh, K., & Sasamata, M. (2007). Vasopressin receptor antagonists: potential indications and clinical results. Current Opinion in Pharmacology, 7(2), 124-9.
Arai Y, et al. Vasopressin Receptor Antagonists: Potential Indications and Clinical Results. Curr Opin Pharmacol. 2007;7(2):124-9. PubMed PMID: 17292670.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vasopressin receptor antagonists: potential indications and clinical results. AU - Arai,Yukinori, AU - Fujimori,Akira, AU - Sudoh,Katsumi, AU - Sasamata,Masao, Y1 - 2007/02/09/ PY - 2006/09/14/received PY - 2006/09/14/accepted PY - 2007/2/13/pubmed PY - 2007/6/6/medline PY - 2007/2/13/entrez SP - 124 EP - 9 JF - Current opinion in pharmacology JO - Curr Opin Pharmacol VL - 7 IS - 2 N2 - Hyponatremia is a common electrolyte disorder with the potential to cause serious neurological complications. Conventional therapies for hyponatremia have been found to be inconsistently effective. Arginine vasopressin (AVP) is etiologically critical for hyponatremia, and it has been proven that AVP receptor (AVP-R) antagonists normalize serum sodium levels in hyponatremic patients. Additionally, one of these drugs showed potential for reducing mortality in patients with decompensated heart failure and for suppressing the progression of genetic renal disease in animals. The first non-peptide AVP-R antagonist has recently been approved in the United States. It is expected that this approval will accelerate the development of future clinical applications of AVP-R antagonists and open the door to a new era in the treatment of these intractable diseases. SN - 1471-4892 UR - https://www.unboundmedicine.com/medline/citation/17292670/Vasopressin_receptor_antagonists:_potential_indications_and_clinical_results_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1471-4892(07)00026-4 DB - PRIME DP - Unbound Medicine ER -